Regulatory Directive: Shaanxi Sunrise operates strictly as a Business-to-Business (B2B) Active Pharmaceutical Ingredient (API) manufacturer. The technical data provided below is exclusively directed at Formulators, QA/QC Directors, R&D Scientists, and Procurement Managers. Our Bupivacaine Hydrochloride (CAS No. 2180-92-9) is for R&D, laboratory, and commercial manufacturing scale-up use only. It is not a finished drug product and is strictly prohibited for direct human or animal consumption.

The parenteral anesthesia supply chain operates on absolute zero tolerance. A single Out-of-Specification (OOS) investigation during your stability testing destroys your quarterly margin. Worse, an FDA Form 483 observation regarding genotoxic impurities or sterile fill-finish contamination shuts down your entire facility. Stop sourcing generic Bupivacaine Hydrochloride based on minor per-kilogram price advantages.

Purchasing untraceable raw materials from unregulated brokers is corporate suicide. When your local anesthetic vials develop microscopic precipitation on the pharmacy shelf, your cheap API suddenly costs you millions in Class I recalls. You require analytical predictability. When you integrate CAS No. 2180-92-9 from Shaanxi Sunrise, you are executing a preemptive technical audit against catastrophic regulatory failure before the material ever enters your ISO 5 cleanroom.

Toxicity is the silent partner in poor Bupivacaine synthesis. The standard manufacturing route involves the reaction of pipecolic acid derivatives with 2,6-dimethylaniline. Sub-standard Bupivacaine Hydrochloride (C₁₈H₂₈N₂O·HCl) consistently suffers from incomplete intermediate elution. 2,6-xylidine is a highly documented, potent genotoxic byproduct.

If your current supplier provides a generic Certificate of Analysis (CoA) that glosses over the specific chromatographic peaks for this mutagenic amine, you are actively gambling with regulatory compliance. Regulatory bodies are aggressively utilizing ICH M7 (R1) guidelines to crack down on mutagenic impurities. We reject industry-standard shortcuts. Our chemical engineering team utilizes a proprietary, multi-stage solvent recrystallization protocol. We test every commercial batch using an Agilent 1260 Infinity II HPLC system. This isolates and eradicates 2,6-xylidine, forcing the degradation profile permanently below 0.005%—well beyond the strictest USP/EP pharmacopeial limits. Absolute purity verified by hard data.

Endotoxin management is the absolute chokepoint for injectable APIs. Many API trading companies source from veterinary-grade facilities masquerading as human-grade GMP labs. Their high-speed jet mills generate extreme friction heat and micro-fissures in the equipment. This structural degradation introduces exogenous pyrogens directly into the batch.

Standard ambient cleanrooms cannot support parenteral demands. Our Bupivacaine undergoes final micronization and packaging exclusively within a cGMP OEL4-rated sterile environment. We conduct rigorous Limulus Amebocyte Lysate (LAL) testing per USP <85> protocols. We mandate a hard endotoxin ceiling of &le; 0.1 IU/mg. This is not a marketing suggestion. It is the inflexible baseline separating clinical-grade anesthetics from unacceptable industrial hazards.

Extended-release pain management relies heavily on advanced liposomal and microsphere injectable suspensions. Formulating these complex delivery systems is incredibly delicate. If your API Particle Size Distribution (PSD) is wildly inconsistent, your formulation is doomed. A D90 parameter that drifts from batch to batch will instantly crash your liposome encapsulation efficiency and ruin the syringeability of your final drug product.

Vials will fail dissolution testing. We provide hyper-targeted micronization services based on your specific formulation equipment. Utilizing wet-dispersion laser diffraction on a Malvern Mastersizer 3000, our QA team guarantees a perfect Gaussian distribution curve. Whether your R&D team requires D90 &le; 10 &mu;m for immediate suspension or custom granular profiles for specialized compounding, we deliver exact geometric consistency.

Imagine your final finished vials sitting in a hospital climate-controlled storage unit. Suddenly, the liquid turns cloudy. You have suffered a polymorphic shift. Generic Bupivacaine often contains unstable metastable polymorphs that look identical under visual inspection but behave erratically when formulated into aqueous solutions.

These metastable crystals slowly rearrange their molecular lattice over time to overcome the thermodynamic energy barrier, dropping out of solution and forming lethal micro-precipitates. We deploy X-Ray Powder Diffraction (XRPD) and Differential Scanning Calorimetry (DSC) to map the crystal lattice of every lot. Our synthetic route strictly isolates the highly stable thermodynamic polymorph. Your injection solutions remain perfectly clear through the entire 36-month shelf life.

Cheap solvent extraction leaves behind a toxic chemical footprint. Aggressive volatile organic compounds (VOCs) like Toluene and Methanol do not simply vanish. They embed themselves deeply within the crystal matrix of the powder. When you process these low-grade APIs, the resulting formulations carry unacceptable organic volatile impurities (OVI).

We refuse to rely on outdated loss-on-drying (LOD) assumptions. Our QA department utilizes advanced Gas Chromatography coupled with Headspace auto-samplers (GC-FID Headspace). We track residual solvents down to the part-per-billion, keeping all traces strictly compliant with USP <467> and ICH Q3C limits.

Audit your raw material specifications. Shaanxi Sunrise provides clinical-grade API metrics to ensure seamless formulation scaling:

Base your procurement and R&D decisions on stringent regulatory standards and clinical data:

• FDA Database: Q3C(R8) Impurities: Guidance for Residual Solvents.
  URL: https://www.fda.gov/regulatory-information/search-fda-guidance-documents

• USP-NF Archive: Bupivacaine Hydrochloride Monograph (USP 43-NF 38).
  URL: https://www.uspnf.com/

• EMA Regulatory Hub: ICH M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities.
  URL: https://www.ema.europa.eu/en/ich-m7-assessment

Yes. We supply comprehensive open-part DMF documentation in eCTD format ready for FDA or EMA portal submission. This includes the complete Route of Synthesis (RoS), detailed impurity profiling, forced degradation studies, and over 36 months of real-time stability data covering both Zone II and Zone IVb climatic conditions.

Packaging is a critical engineering discipline, not an afterthought. We seal the API inside pharmaceutical-grade, FDA-approved double-layered antistatic Low-Density Polyethylene (LDPE) bags. These bags are vacuum-purged, nitrogen-flushed, hermetically sealed, and placed inside a medical-grade Tyvek pouch. The entire unit is secured inside heavy-duty rigid fiber drums with tamper-evident serial seals. We also embed TempTale dataloggers within the pallet to provide your receiving QA team with a continuous temperature map.

We enforce draconian control over chiral starting materials. For racemic Bupivacaine, we utilize highly specific chiral chromatography columns to monitor the R/S configuration ratio constantly. If your pipeline requires the pure enantiomer Levobupivacaine, our chiral purity threshold is strictly &ge; 99.5%, ensuring absolute anesthetic precision for your formulations.

Yes. Epidural blocks require the absolute highest echelon of endotoxin and bioburden control. Because our manufacturing and milling processes eliminate exogenous pyrogens down to &le; 0.1 IU/mg, our API is routinely audited and selected by pharmaceutical manufacturers for ultra-sensitive neuraxial blockade formulation lines.

Stop Gambling With Your Sterile Fill-Finish Lines

Substandard raw materials will eventually destroy your product pipeline. Every failed lot costs your pharmaceutical plant factory downtime, wasted operational labor, and permanent market reputation damage. Cut out the middleman trading companies who manipulate paperwork and obscure the true origin of their chemicals. Upgrade to pharmaceutical-grade predictability.

Ready to secure your clinical-standard API for commercial scale-up? Contact the Shaanxi Sunrise technical engineering team today to demand our full technical analytical audit report before you validate your next production run.